TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies1-9. Adults with T cell leukaemias and lymphomas, collectively called T cell cancers, have short survival10,11 and lack such targeted therapies. Thus, T cell cancers particularly warrant the development of CAR T cells and antibodies to improve patient outcomes. Preclinical studies showed that targeting T cell receptor β-chain constant region 1 (TRBC1) can kill cancerous T cells while preserving sufficient healthy T cells to maintain immunity12, making TRBC1 an attractive target to treat T cell cancers. However, the first-in-human clinical trial of anti-TRBC1 CAR T cells reported a low response rate and unexplained loss of anti-TRBC1 CAR T cells13,14. Here we demonstrate that CAR T cells are lost due to killing by the patient's normal T cells, reducing their efficacy. To circumvent this issue, we developed an antibody-drug conjugate that could kill TRBC1+ cancer cells in vitro and cure human T cell cancers in mouse models. The anti-TRBC1 antibody-drug conjugate may provide an optimal format for TRBC1 targeting and produce superior responses in patients with T cell cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:628 |
|---|---|
| Enthalten in: |
Nature - 628(2024), 8007 vom: 10. Apr., Seite 416-423 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nichakawade, Tushar D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Immunoconjugates |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 24.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41586-024-07233-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370283309 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370283309 | ||
| 003 | DE-627 | ||
| 005 | 20240425233335.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240329s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41586-024-07233-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370283309 | ||
| 035 | |a (NLM)38538786 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nichakawade, Tushar D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies1-9. Adults with T cell leukaemias and lymphomas, collectively called T cell cancers, have short survival10,11 and lack such targeted therapies. Thus, T cell cancers particularly warrant the development of CAR T cells and antibodies to improve patient outcomes. Preclinical studies showed that targeting T cell receptor β-chain constant region 1 (TRBC1) can kill cancerous T cells while preserving sufficient healthy T cells to maintain immunity12, making TRBC1 an attractive target to treat T cell cancers. However, the first-in-human clinical trial of anti-TRBC1 CAR T cells reported a low response rate and unexplained loss of anti-TRBC1 CAR T cells13,14. Here we demonstrate that CAR T cells are lost due to killing by the patient's normal T cells, reducing their efficacy. To circumvent this issue, we developed an antibody-drug conjugate that could kill TRBC1+ cancer cells in vitro and cure human T cell cancers in mouse models. The anti-TRBC1 antibody-drug conjugate may provide an optimal format for TRBC1 targeting and produce superior responses in patients with T cell cancers | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell, alpha-beta |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a TRBC1 protein, human |2 NLM | |
| 700 | 1 | |a Ge, Jiaxin |e verfasserin |4 aut | |
| 700 | 1 | |a Mog, Brian J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Bum Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Pearlman, Alexander H |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Michael S |e verfasserin |4 aut | |
| 700 | 1 | |a DiNapoli, Sarah R |e verfasserin |4 aut | |
| 700 | 1 | |a Wyhs, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Marcou, Nikita |e verfasserin |4 aut | |
| 700 | 1 | |a Glavaris, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Konig, Maximilian F |e verfasserin |4 aut | |
| 700 | 1 | |a Gabelli, Sandra B |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Evangeline |e verfasserin |4 aut | |
| 700 | 1 | |a Sterling, Cole |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner-Johnston, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Rozati, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Swinnen, Lode |e verfasserin |4 aut | |
| 700 | 1 | |a Fuchs, Ephraim |e verfasserin |4 aut | |
| 700 | 1 | |a Pardoll, Drew M |e verfasserin |4 aut | |
| 700 | 1 | |a Gabrielson, Kathy |e verfasserin |4 aut | |
| 700 | 1 | |a Papadopoulos, Nickolas |e verfasserin |4 aut | |
| 700 | 1 | |a Bettegowda, Chetan |e verfasserin |4 aut | |
| 700 | 1 | |a Kinzler, Kenneth W |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Shibin |e verfasserin |4 aut | |
| 700 | 1 | |a Sur, Surojit |e verfasserin |4 aut | |
| 700 | 1 | |a Vogelstein, Bert |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Suman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature |d 1945 |g 628(2024), 8007 vom: 10. Apr., Seite 416-423 |w (DE-627)NLM000008257 |x 1476-4687 |7 nnns |
| 773 | 1 | 8 | |g volume:628 |g year:2024 |g number:8007 |g day:10 |g month:04 |g pages:416-423 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41586-024-07233-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 628 |j 2024 |e 8007 |b 10 |c 04 |h 416-423 | ||